Co-Diagnostics Secures Up to $3.1M Convertible Financing; Sets ATM Sweep, Collateral and Registration Terms
Co-Diagnostics secured up to $3.1M in senior secured convertible notes from J.J. Astor & Co., with $2.1M initially funded. The notes have a 1.35x factor, 30 weekly installments, and are backed by a senior-priority lien and subsidiary guarantees. The company also agreed to an ATM proceeds waterfall and a registration rights deal for resale of conversion-related shares. Maxim Group was engaged as placement agent.
How this was made
The 30-second read
Why it matters
The financing adds senior debt and potential equity conversion, which may dilute existing shareholders and increase leverage.
Market read
A micro‑cap biotech raises modest convertible financing, likely causing short‑term price pressure.
What to watch
Details on use of proceeds and conversion terms are not disclosed, which could affect the actual impact.
Background
Co-Diagnostics is a clinical diagnostics company seeking liquidity through convertible debt.
Ticker impact
Co-Diagnostics announced a senior secured convertible financing of up to $3.1M, including $2.1M funded and an option for $1M more.
likely pressure as the market prices in dilution and added leverage
Convertible financing at a modest size for a micro‑cap suggests short‑term share‑price downside due to dilution risk.
Market effects
Limited impact; similar biotech financing trends may be noted by sector investors.
US micro‑cap biotech space sees modest funding activity.
Low; the financing is company‑specific and not macro‑driven.
Counterpoint
If the capital is used for a breakthrough product, the dilution could be offset by future upside.
Key entities
- FinancierJ.J. Astor & Co.
Lead arranger of the convertible loan.
- Placement AgentMaxim Group
Handles ATM proceeds waterfall and placement.
